Since BCL7A expression is highly enriched in mesenchymal GBM and strongly associated with immune response in glioma, we attempted to explore whether BCL7A functioned as a predictive biomarker for positive adjuvant chemotherapy response. Here, BCL7A is linked to central nervous system cancer.